Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We investigated the effects of atorvastatin on the lipid and the apoA-I-containing HDL subpopulation profiles in 86 patients with established coronary heart disease (CHD). The entire drug treatment period lasted 12 weeks (4-week periods of 20 then 40, then 80 mg/day). Each dose of atorvastatin treatment resulted in significant reductions in plasma total-C, LDL-C, and triglyceride (TG), and non-significant increases in HDL-C levels compared with placebo treatment. ApoA-I levels did not change significantly during any of the treatment periods. Despite the modest increase of HDL-C (6%, 7%, 5%) and no change in apoA-I levels, the distribution of the apoA-I-containing HDL subpopulations changed significantly during each treatment period. There were significant increases in the concentrations of the large LpA-I alpha-1 (24%, 39%, 26%) and pre alpha-1 (51%, 61%, 63%) subpopulations at the expense of the small lipoprotein LpA-I:A-II alpha-3 subpopulations which decreased on all doses, and the decreases were significant on the 40 and 80 mg/day doses (6%, 5%). Atorvastatin influences the lipid-related risk for CHD in two ways: first, it significantly decreases LDL-C and TG levels while increasing HDL-C, and second, it significantly shifts the HDL subpopulation profile of CHD patients toward that observed in subjects without CHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
Cholesterol Reduction Yields Clinical Benefit: Impact of Statin Trials
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1998) · Circulation · doi:10.1161/01.cir.97.10.946 · Cited by 442
Sweetnam, P. M., Bolton, C. H., Yarnell, J. W., Bainton, D., Baker, I. A., Elwood, P. C., & Miller, N. E. (1994) · Circulation · doi:10.1161/01.cir.90.2.769 · Cited by 98
Cited by
Unique Lipoprotein Phenotype and Genotype Associated With Exceptional Longevity
Barzilai, N. (2003) · JAMA · doi:10.1001/jama.290.15.2030 · Cited by 575
Asztalos, B. F., Cupples, L. A., Demissie, S., Horvath, K. V., Cox, C. E., Batista, M. C., & Schaefer, E. J. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000146325.93749.a8 · Cited by 298
Self-citationAsztalos, B. F., Collins, D., Cupples, L. A., Demissie, S., Horvath, K. V., Bloomfield, H. E., Robins, S. J., & Schaefer, E. J. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000183727.90611.4f · Cited by 268
Self-citationBarter, P. J., Brandrup-Wognsen, G., Palmer, M. K., & Nicholls, S. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p002816 · Cited by 259
High-density lipoprotein subfractions and risk of coronary artery disease
Morgan, J., Carey, C., Lincoff, A., & Capuzzi, D. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0047-0 · Cited by 75
Metadata
- Authors
- Asztalos, B. F., Horvath, K. V., McNamara, J. R., Roheim, P. S., Rubinstein, J. J., & Schaefer, E. J.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2002-10
- Volume
- 43
- Issue
- 10
- Pages
- 1701-1707
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2116876956
- Cited by
- 65
- References
- 4
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.